SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-21-028235
Filing Date
2021-11-12
Accepted
2021-11-12 17:15:28
Documents
84
Period of Report
2021-09-30

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 1323440
2 ex31-1.htm EX-31.1 18307
3 ex31-2.htm EX-31.2 17800
4 ex32-1.htm EX-32.1 7587
5 ex32-2.htm EX-32.2 7530
  Complete submission text file 0001493152-21-028235.txt   7255099

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE prph-20210930.xsd EX-101.SCH 61393
7 XBRL CALCULATION FILE prph-20210930_cal.xml EX-101.CAL 92880
8 XBRL DEFINITION FILE prph-20210930_def.xml EX-101.DEF 261339
9 XBRL LABEL FILE prph-20210930_lab.xml EX-101.LAB 483120
10 XBRL PRESENTATION FILE prph-20210930_pre.xml EX-101.PRE 385388
11 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 1136954
Mailing Address 711 STEWART AVE, SUITE 200 GARDEN CITY NEW YORK NY 11530
Business Address 711 STEWART AVE, SUITE 200 GARDEN CITY NEW YORK NY 11530 (215) 345-0919
ProPhase Labs, Inc. (Filer) CIK: 0000868278 (see all company filings)

IRS No.: 232577138 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-21617 | Film No.: 211404847
SIC: 2834 Pharmaceutical Preparations